4.6 Review

Emerging role of interleukin-22 in autoimmune diseases

Journal

CYTOKINE & GROWTH FACTOR REVIEWS
Volume 24, Issue 1, Pages 51-57

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2012.07.002

Keywords

IL-22; Th17; Th22; Autoimmune; Therapeutic

Funding

  1. National Natural Science Foundation of China [81102192, 30830089]
  2. Specialized Research Fund for the Doctoral Program of Higher Education of China [20113420120008]
  3. Grants for Scientific Research of BSKY from Anhui Medical University [XJ201014]
  4. National Institute of Health [AR059103, AI084359]
  5. ACR
  6. Arthritis Foundation
  7. Wright Foundation

Ask authors/readers for more resources

Interleukin-22 (IL-22) is an IL-10 family cytokine member that was recently discovered to be mainly produced by Th17 cells. Previous studies have indicated the importance of IL-22 in host defense against Gram-negative bacterial organisms (in gut and lung). Recently, there is emerging evidence that IL-22 is involved in the development and pathogenesis of several autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), Sjogren's syndrome (SS) and psoriasis. Therapeutics targeting IL-22 therefore may have promise for treating various autoimmune diseases. In this review, we discuss the recent progression of the involvement of IL-22 in the development and pathogenesis of autoimmune diseases, as well as its clinical implications and therapeutic potential. (C) 2012 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available